Symbols

OPK

OPKO Health·NASDAQ

--(--)

OPK fundamentals

OPK Q4 2025 Earnings

OPKO Health (OPK) released its earnings on Feb 26, 2026: revenue was 148.50M (YoY -19.12%), beat estimates; EPS was -0.04 (YoY -500.00%), beat estimates.

Revenue / YoY

148.50M

-19.12%

EPS / YoY

-0.04

-500.00%

Report date

Feb 26, 2026

OPK Earnings Call Summary for Q4,2025

Strategic Restructuring Success: BioReference divestiture reduced costs, positioning for 2026 profitability with 4Kscore growth.
Therapeutic Pipeline Momentum: 3 clinical-stage programs (EBV, MDX2001, MDX2004) and $1+ billion Regeneron collaboration.
Financial Strength: $369M cash, $47M buybacks, and 2026 revenue guidance of $530-560M.
Key Catalysts: Phase Ib MDX2001 trials, EBV Phase II decision, and CAR-T platform partnerships.

Earnings

EPS

Revenue

Revenue & Expenses

OPK has released its 2025 Q4 earnings report, with revenue of 148.45M, reflecting a YoY change of -19.16%, and net profit of -31.26M, showing a YoY change of -322.83%. The Sankey diagram below clearly presents OPK's revenue sources and cost distribution.

Key Indicators

OPKO Health (OPK) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

OPKO Health (OPK)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

OPKO Health (OPK)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

OPKO Health (OPK)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown